SCHEMBL7140488

SCHEMBL7140488

COC(=O)c1ccc(NCC(=O)CN(C)C(=O)C2CC(SC(C)=O)CN2S(=O)(=O)c2cccs2)cc1

nearest known ligand 0.40

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.40
RAB9A P51151 4/20 0.39
ELOVL6 Q9H5J4 1/20 0.36
HPGD P15428 2/20 0.35
LMNA P02545 1/20 0.35
NPC1 O15118 2/20 0.34
MAPT P10636 1/20 0.34
MME P08473 1/20 0.34
ACE P12821 1/20 0.34
ECE1 P42892 1/20 0.34
LIMK2 P53671 1/20 0.34
KMT2A Q03164 2/20 0.33
MEN1 O00255 1/20 0.33
AGTR1 P30556 1/20 0.32
SMN1; SMN2 Q16637 1/20 0.32
POLB P06746 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7150245 0.88 MME (0.45) ALDH1A1RAB9AELOVL6HPGDLMNA
SCHEMBL7148898 0.88 MME (0.40) ALDH1A1RAB9AELOVL6HPGDLMNA
SCHEMBL7136621 0.86 RAB9A (0.40) ALDH1A1RAB9AELOVL6HPGDLMNA
SCHEMBL7136624 0.86 RAB9A (0.40) ALDH1A1RAB9AELOVL6HPGDLMNA
SCHEMBL7145216 0.85 MME (0.40) ALDH1A1RAB9AHPGDLMNANPC1
SCHEMBL7140148 0.85 MME (0.38) ALDH1A1RAB9AELOVL6HPGDNPC1
SCHEMBL7148392 0.84 CA1 (0.38) ALDH1A1RAB9AHPGDLMNANPC1
SCHEMBL7144462 0.84 MME (0.38) ALDH1A1RAB9AHPGDLMNANPC1
SCHEMBL7136630 0.83 MME (0.34) ALDH1A1RAB9AHPGDLMNANPC1
SCHEMBL7141603 0.83 POLB (0.39) ALDH1A1MMEACEECE1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1303485-A1 PYRROLIDINE DERIVATIVES AS INHIBITORS OF ENDOTHELIN-CONVERTING ENZYME F. HOFFMANN-LA ROCHE AG (CH) 2003-04-23 EP disclosed
US-6541638-B2 (2S,4S)-1-(4-Mercapto-1-(naphthalene-2-sulfonyl)-pyrrolidine-2 -carbonyl)-piperidine-4-carboxylic acid ethyl ester for example; zinc protease inhibitors; for treating diseases associated with vasoconstriction HOFFMAN-LA ROCHE INC. 2003-04-01 US disclosed
US-20020049243-A1 Pyrrolidine derivatives HOFFMANN-LA ROCHE INC. 2002-04-25 US disclosed
WO-2002006222-A1 PYRROLIDINE DERIVATIVES AS INHIBITORS OF ENDOTHELIN-CONVERTING ENZYME F. HOFFMANN-LA ROCHE AG (CH) 2002-01-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020049243-A1 Pyrrolidine derivatives PREP, PEPD, DNPEP ALDH1A1 767/4885RAB9A 2425/4885ELOVL6 2350/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.